TTrialPathMatch Me to Trials
← Back to trials
RecruitingPsoriasisCondyloma AcuminataBiotherapies

Effect of Anti-Psoriatic Biologics on Risk of Anogenital Warts (CONDYPSO)

Eligible age

18+ yrs

Accepts

All genders

Locations

0 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This study aims to assess the impact of anti-TNF-α, anti-IL-17, and anti-IL-23 biologic therapies on the risk of development or recurrence of anogenital warts (AGW) in patients with moderate to severe psoriasis. By modulating systemic and mucosal immunity, these treatments may alter host defenses against human papillomavirus (HPV) infections, which are responsible for AGW. In particular, inhibition of Th1 pathways (by anti-TNF-α) and Th17 pathways (by anti-IL-17 and anti-IL-23), both central to the antiviral response, may reduce local production of pro-inflammatory cytokines (such as IFN-γ, IL-17, and IL-22), decrease the activity of CD8+ cytotoxic T lymphocytes, and impair dendritic cell function, thereby compromising viral clearance at the genital mucosa. AGW are a frequent and recurrent manifestation of HPV infection, and their incidence may be influenced by these immunomodulatory treatments. The retrospective component will review cases already documented in medical records and analyze, to the extent permitted by available data, the same risk factors as in the prospective component, including history of sexually transmitted infections (STIs), risk behaviors, treatments used (systemic or topical), and time to onset or recurrence of AGW. This analysis will be conducted as a retrospective case-control study, matching each patient who developed AGW with one or more controls receiving biologics who did not develop AGW, in order to identify factors associated with their occurrence. The prospective follow-up will assess, over 24 months, risk factors for occurrence or recurrence of AGW in patients with moderate to severe psoriasis, according to the treatment received: no treatment, topical treatment, systemic non-immunomodulatory treatment, or immunomodulatory treatment, including biologics. Acceptability of HPV vaccination will also be evaluated, at enrollment, in a subset of prospectively included adult patients without a known history or current clinical lesion of condyloma, HSIL, or HPV-induced carcinoma.

Sponsor: Jonathan Krygier

You may qualify if…

  • ✓ Age ≥ 18 years
  • ✓ Moderate to severe psoriasis (BSA \> 10% or PASI \> 10), prior to initiation of the current therapy at the time of inclusion
  • ✓ Planned dermatological follow-up for approximately 24 months, with no additional visits required by the study
  • ✓ Signed informed consent

You may not qualify if…

  • ✕ Severe immunosuppression not related to psoriasis or its therapy (concomitant treatment with major immunosuppressants, uncontrolled HIV infection, or other conditions inducing significant immunosuppression)

Source: ClinicalTrials.gov · NCT07234838 · last updated 2026-03-18

Effect of Anti-Psoriatic Biologics on Risk of Anogenital Warts (CONDYP · TrialPath